Literature DB >> 19729173

Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis.

Akiyuki Uzawa1, Masahiro Mori, Yuhta Iwai, Makoto Kobayashi, Sei Hayakawa, Naoki Kawaguchi, Satoshi Kuwabara.   

Abstract

We describe 2 patients who developed anti-aquaporin-4 antibody-positive neuromyelitis optica (NMO) following the development of anti-acetylcholine receptor antibody-positive myasthenia gravis (MG). A literature review of 13 similar cases in addition to the present 2 cases of NMO with MG showed predominance among Asian women and frequent development of NMO following thymectomy for MG. Moreover, in one of our patients, serial assays of anti-aquaporin-4 antibody and anti-acetylcholine receptor antibody were performed. Accumulating evidence for the coexistence of NMO and MG suggests that a common immunopathogenesis of NMO and MG may exist, and the association of NMO with MG may be more frequent than hitherto believed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729173     DOI: 10.1016/j.jns.2009.08.040

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

1.  Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report.

Authors:  Masahiro Mori; Naoki Kawaguchi; Akiyuki Uzawa; Yuhko Nemoto; Saeko Masuda; Satoshi Kuwabara
Journal:  J Neurol       Date:  2011-11-08       Impact factor: 4.849

Review 2.  Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.

Authors:  Eduardo Freitas; Joana Guimarães
Journal:  Rheumatol Int       Date:  2014-06-22       Impact factor: 2.631

3.  Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.

Authors:  Kimitoshi Kimura; Yoichiro Okada; Chihiro Fujii; Kenichi Komatsu; Ryosuke Takahashi; Sadayuki Matsumoto; Takayuki Kondo
Journal:  J Neurol       Date:  2019-07-24       Impact factor: 4.849

4.  Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.

Authors:  M I Leite; E Coutinho; M Lana-Peixoto; S Apostolos; P Waters; D Sato; L Melamud; M Marta; A Graham; J Spillane; A M Villa; D Callegaro; E Santos; A Martins da Silva; S Jarius; R Howard; I Nakashima; G Giovannoni; C Buckley; D Hilton-Jones; A Vincent; J Palace
Journal:  Neurology       Date:  2012-05-02       Impact factor: 9.910

5.  Neuromyelitis optica and myasthenia gravis in a young Nigerian girl.

Authors:  Salisu Abdullahi Balarabe; Mohammad Dantani Adamu; Musa Mamman Watila; Nma Jiya
Journal:  BMJ Case Rep       Date:  2015-09-03

Review 6.  Aquaporin and brain diseases.

Authors:  Jérôme Badaut; Andrew M Fukuda; Amandine Jullienne; Klaus G Petry
Journal:  Biochim Biophys Acta       Date:  2013-10-26

Review 7.  Aquaporin 4: a player in cerebral edema and neuroinflammation.

Authors:  Andrew M Fukuda; Jerome Badaut
Journal:  J Neuroinflammation       Date:  2012-12-27       Impact factor: 8.322

8.  Myasthenia Gravis during the Course of Neuromyelitis Optica.

Authors:  Masoud Etemadifar; Seyed-Hossein Abtahi; Alireza Dehghani; Mohammad-Ali Abtahi; Mojtaba Akbari; Nasim Tabrizi; Tannaz Goodarzi
Journal:  Case Rep Neurol       Date:  2011-10-21

9.  Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.

Authors:  Sven Jarius; Klemens Ruprecht; Brigitte Wildemann; Tania Kuempfel; Marius Ringelstein; Christian Geis; Ingo Kleiter; Christoph Kleinschnitz; Achim Berthele; Johannes Brettschneider; Kerstin Hellwig; Bernhard Hemmer; Ralf A Linker; Florian Lauda; Christoph A Mayer; Hayrettin Tumani; Arthur Melms; Corinna Trebst; Martin Stangel; Martin Marziniak; Frank Hoffmann; Sven Schippling; Jürgen H Faiss; Oliver Neuhaus; Barbara Ettrich; Christian Zentner; Kersten Guthke; Ulrich Hofstadt-van Oy; Reinhard Reuss; Hannah Pellkofer; Ulf Ziemann; Peter Kern; Klaus P Wandinger; Florian Then Bergh; Tobias Boettcher; Stefan Langel; Martin Liebetrau; Paulus S Rommer; Sabine Niehaus; Christoph Münch; Alexander Winkelmann; Uwe K Zettl U; Imke Metz; Christian Veauthier; Jörn P Sieb; Christian Wilke; Hans P Hartung; Orhan Aktas; Friedemann Paul
Journal:  J Neuroinflammation       Date:  2012-01-19       Impact factor: 8.322

10.  NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness.

Authors:  Tehila Mizrachi; Livnat Brill; Malcolm Rabie; Yoram Nevo; Yakov Fellig; Mayan Zur; Dimitrios Karussis; Oded Abramsky; Talma Brenner; Adi Vaknin-Dembinsky
Journal:  J Immunol Res       Date:  2018-05-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.